{"protocolSection": {"identificationModule": {"nctId": "NCT01302691", "orgStudyIdInfo": {"id": "0954E-357"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "MK-0954E Study in Participants With Hypertension (MK-0954E-357)", "officialTitle": "A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration"}, "statusModule": {"statusVerifiedDate": "2019-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-04-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-04-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-02-22", "studyFirstSubmitQcDate": "2011-02-23", "studyFirstPostDateStruct": {"date": "2011-02-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-12-05", "resultsFirstSubmitQcDate": "2016-12-05", "resultsFirstPostDateStruct": {"date": "2017-01-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-02-28", "lastUpdatePostDateStruct": {"date": "2019-03-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E). The primary hypothesis is that L50/H12.5/A5 is more effective in lowering mean trough sitting diastolic blood pressure (SiDBP) after 8 weeks of treatment compared to L50+A5 in Japanese participants with essential hypertension who are not adequately controlled following an 8-week treatment with filter period study drug (L50+A5)."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Essential hypertension", "Uncontrolled hypertension", "Antihypertensive agents", "Blood pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 327, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "L50/H12.5/A5", "type": "EXPERIMENTAL", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.", "interventionNames": ["Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)", "Drug: Placebo to losartan potassium", "Drug: Placebo to amlodipine besylate"]}, {"label": "L50 + A5", "type": "ACTIVE_COMPARATOR", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.", "interventionNames": ["Drug: Losartan potassium", "Drug: Amlodipine besylate", "Drug: Placebo to MK-0954E"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)", "description": "One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.", "armGroupLabels": ["L50/H12.5/A5"]}, {"type": "DRUG", "name": "Losartan potassium", "description": "One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.", "armGroupLabels": ["L50 + A5"]}, {"type": "DRUG", "name": "Amlodipine besylate", "description": "One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.", "armGroupLabels": ["L50 + A5"]}, {"type": "DRUG", "name": "Placebo to MK-0954E", "description": "One tablet, containing placebo, orally, once daily, for 8 weeks.", "armGroupLabels": ["L50 + A5"]}, {"type": "DRUG", "name": "Placebo to losartan potassium", "description": "One tablet, containing placebo, orally, once daily, for 8 weeks.", "armGroupLabels": ["L50/H12.5/A5"]}, {"type": "DRUG", "name": "Placebo to amlodipine besylate", "description": "One capsule, containing placebo, orally, once daily, for 8 weeks.", "armGroupLabels": ["L50/H12.5/A5"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)", "description": "Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants Who Experience \u22651 Adverse Event (AE)", "description": "An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)"}, {"measure": "Percentage of Participants Who Experience \u22651 Drug-related AE", "description": "An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)"}, {"measure": "Percentage of Participants Who Experience \u22651 Serious Adverse Event (SAE)", "description": "An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)"}, {"measure": "Percentage of Participants Who Experience \u22651 Drug-related SAE", "description": "An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)"}, {"measure": "Percentage of Participants Who Had Study Drug Stopped Due to an AE", "description": "An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm", "timeFrame": "up to 8 weeks"}], "secondaryOutcomes": [{"measure": "Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)", "description": "Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.", "timeFrame": "Baseline and Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Participant has a diagnosis of essential hypertension.\n* Participant is being treated with single or dual treatment for hypertension and will be able to discontinue the prior antihypertensive medication.\n* Participant has a mean trough SiDBP of \u2265 90 mmHg and \\< 110 mmHg.\n* Participant has a mean trough SiSBP of \u2265 140 mmHg and \\< 200 mmHg.\n* Participant has no clinically significant abnormality at screening visit.\n\nExclusion criteria\n\n* Participant is currently taking \\> 2 antihypertensive medications.\n* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug, and thiazide drug or related drug (i.e., sulfonamide-containing \"chlortalidone\" medicines).\n* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence.\n* Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy test is positive at screening visit (Visit 1).\n* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "25271811", "type": "RESULT", "citation": "Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Clin Exp Hypertens. 2015;37(3):260-6. doi: 10.3109/10641963.2014.954712. Epub 2014 Oct 1."}, {"pmid": "25716649", "type": "RESULT", "citation": "Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. Hypertens Res. 2015 May;38(5):329-35. doi: 10.1038/hr.2015.3. Epub 2015 Feb 26."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All participants received single-blind losartan 50 mg (L50) + amlodipine 5 mg (A5) and placebo for L50/(H12.5)/A5 during 8-week Filter/Screening Period. A total of 707 entered the Filter/Screening Period and 327 were randomly assigned to 1 of the 2 treatment arms for the Double-blind Treatment Period.", "groups": [{"id": "FG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "FG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "164"}, {"groupId": "FG001", "numSubjects": "163"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "154"}, {"groupId": "FG001", "numSubjects": "157"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Blood Pressure/Potassium Criteria Met", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "BG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "164"}, {"groupId": "BG001", "value": "163"}, {"groupId": "BG002", "value": "327"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.9", "spread": "9.4"}, {"groupId": "BG001", "value": "55.4", "spread": "10.1"}, {"groupId": "BG002", "value": "55.2", "spread": "9.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "74"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "253"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)", "description": "Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.", "populationDescription": "All participants that received at least one dose of study treatment, had at least 1 post-randomization observation for the analysis endpoint, and had baseline data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.1", "lowerLimit": "-10.2", "upperLimit": "-7.9"}, {"groupId": "OG001", "value": "-8.0", "lowerLimit": "-9.1", "upperLimit": "-6.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.205", "statisticalMethod": "Constrained Longitudinal Data Analysis", "statisticalComment": "Model includes treatment group, time point, and the interaction of time by treatment with restriction of same baseline mean across treatment groups", "paramType": "Difference in Least Squares Means", "paramValue": "-1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.7", "ciUpperLimit": "0.6"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experience \u22651 Adverse Event (AE)", "description": "An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.5"}, {"groupId": "OG001", "value": "28.8"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experience \u22651 Drug-related AE", "description": "An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.6"}, {"groupId": "OG001", "value": "3.7"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experience \u22651 Serious Adverse Event (SAE)", "description": "An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.6"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experience \u22651 Drug-related SAE", "description": "An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "up to 14 days after last dose of study drug (up to 10 weeks)", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Had Study Drug Stopped Due to an AE", "description": "An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "up to 8 weeks", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2"}, {"groupId": "OG001", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)", "description": "Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.", "populationDescription": "All participants that received at least one dose of study treatment, had at least 1 post-randomization observation for the analysis endpoint, and had baseline data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}, {"id": "OG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.4", "lowerLimit": "-15.2", "upperLimit": "-11.6"}, {"groupId": "OG001", "value": "-10.2", "lowerLimit": "-12.0", "upperLimit": "-8.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "statisticalMethod": "Constrained Longitudinal Data Analysis", "statisticalComment": "Model includes treatment group, time point, and the interaction of time by treatment with restriction of same baseline mean across treatment groups", "paramType": "Difference in Least Squares Means", "paramValue": "-3.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.7", "ciUpperLimit": "-0.8"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "up to 2 weeks after last dose of study drug (up to 10 weeks)", "description": "All participants that received at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "L50/H12.5/A5", "description": "Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 164, "otherNumAffected": 11, "otherNumAtRisk": 164}, {"id": "EG001", "title": "L50 + A5", "description": "Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 163, "otherNumAffected": 15, "otherNumAtRisk": 163}], "seriousEvents": [{"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 164}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 164}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 164}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 164}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 164}, {"groupId": "EG001", "numEvents": 15, "numAffected": 15, "numAtRisk": 163}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck, Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}